Lestaurtinib

Base Information

• Chemical Name: Lestaurtinib
• CAS No.: 111358-88-4
• Deprecated CAS: 156256-78-9
• Molecular Formula: C26H21N3O4
• Molecular Weight: 439.47
• Hs Code.: 2934999090
• UNII: DO989GC5D1
• DSSTox Substance ID: DTXSID5046778
• Wikipedia: Lestaurtinib
• Wikidata: Q6531771
• NCI Thesaurus Code: C48402
• Pharos Ligand ID: JJKPSGPHHFRR
• ChEMBL ID: CHEMBL603469
• Mol file: 111358-88-4.mol

Synonyms:CEP 701;CEP-701;CEP701;KT-555;KT-5555;KT5555;lestaurtinib;SP-924;SP924;SPM-924

Chemical Property of Lestaurtinib

Chemical Property:

• Appearance/Colour: Off-white solid
• Vapor Pressure: 0mmHg at 25°C
• Melting Point: 215-220 °C
• Refractive Index: 1.88
• Boiling Point: 723 °C at 760mmHg
• PKA: 13.37±0.40(Predicted)
• Flash Point: 391 °C
• PSA: 88.65000
• Density: 1.7g/cm³
• LogP: 3.80320
• Storage Temp.: Desiccate at -20°C
• Solubility.: DMSO: >10mg/mL
• XLogP3: 2.2
• Hydrogen Bond Donor Count: 3
• Hydrogen Bond Acceptor Count: 4
• Rotatable Bond Count: 1
• Exact Mass: 439.15320616
• Heavy Atom Count: 33
• Complexity: 886

Purity/Quality:

98%,99%, ^*data from raw suppliers

Lestaurtinib ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: CC12C(CC(O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)(CO)O
• Isomeric SMILES: C[C@@]12[C@](C[C@@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)(CO)O
• Recent ClinicalTrials: N2001-03: CEP-701 in Treating Young Patients With Recurrent or Refractory High-Risk Neuroblastoma
• Recent EU Clinical Trials: A phase IIa, multi-center, randomized, double-blind, vehicle-controlled study to determine antipsoriatic efficacy and safety of topical CEP-701 (lestaurtinib) cream formulations in patients with psoriasis vulgaris
• Description: Lestaurtinib (111358-88-4) is a potent and selective FLT3 inhibitor (IC50= 2 nM).1,2?Inhibits RET and RET phosphorylation in medullary thyroid carcinoma cells.3?Suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders.4?Potent Trk inhibitor.5?Cell permeable.
• Uses: Lestaurtinib is used for the treatment of pancreatic cancer and acute myelogenous leukaemia (AML) It is used for the treatment of pancreatic cancer and acute myelogenous leukaemia (AML). CEP-701 hydrate has been used as a tyrosine kinase inhibitor:to study its effects on early growth response protein (EGR) genes and nerve growth factor (NGF) stimulation in human epithelial cellsas a supplement in reservoir solution for co-crystallization studies with human receptor-interacting?protein kinase?4 (RIPK4)as an FMS-like tyrosine kinase 3 (FLT3) inhibitor-gold nanoparticle conjugate to study its effects on acute myeloid leukemia

Technology Process of Lestaurtinib

There total 1 articles about Lestaurtinib which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield: 81.0%

K-252a (99533-80-9,97161-97-2) → lestaurtinib (111358-88-4)

Guidance literature:

With lithium borohydride; In tetrahydrofuran; at 20 ℃;

DOI:10.1016/S0960-894X(02)00638-8 DOI:10.1021/jm040178m

Reference yield: 87.0%

13-cis-retinoyloxyacetic acid + lestaurtinib (111358-88-4) → C48H49N3O7

Guidance literature:

With dicyclohexyl-carbodiimide; 4-(dimethylamino)pyridinium tosylate; In dichloromethane; at 0 - 20 ℃; for 3.83333h; Inert atmosphere;

Reference yield:

Hippuric Acid (495-69-2,140480-84-8,21251-67-2,91787-63-2,66407-11-2) + lestaurtinib (111358-88-4) → Lestaurtinib*hippuric acid (1173839-24-1)

Guidance literature:

In methoxybenzene; at 20 - 50 ℃; for 25.5h; Product distribution / selectivity; Grounding at 5, 10 and 15 Hz oscillation frequency;

upstream raw materials:

K-252a

Downstream raw materials:

K252a

Lestaurtinib*hippuric acid

Refernces

• 1、 -. "PROCESS TO MAKE LESTAURTINIB". Page/Page column 5-6. . Retrieved 2008/12/07.